New Drug Futures: Vaccines published by Espicom Business Intelligence in May, 2006. This report consists of 48 PAGES and the price starts from US $ 1320.
Abstract
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the vaccines sector. The report
includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
We estimate that vaccines generated sales of over US$10.6 billion in 2005,
with over 50% derived from traditional, domestic paediatric vaccines and the
development of novel vaccines that can command price premiums.
The market is beginning to turn around after a period of slow growth and it is
forecast to be worth nearly US$20 billion by 2010. Growth will be driven
principally by the adolescent and adult vaccine segment of the market as well
as the development of therapeutic vaccines.
The market has attracted the attention of eleven pharma players, with six of
these accounting for around 90% of vaccine sales by value.
Table of Contents
CURRENT MARKET SIZE
Vaccine Sales breakdown and forecasts
ADDRESSABLE PATIENT POPULATION
PAEDIATRIC VACCINES
ADULT VACCINES
CERVICAL CANCER VACCINES
LUNG CANCER VACCINES
PROSTATE CANCER VACCINES
CURRENT TREATMENTS
VACCINE SALES DRIVERS
VACCINE SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY VACCINE LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY VACCINE LAUNCHES BY 2010
- Cervarix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Gardasil (Merck & Co/sanofi pasteur)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- GVAX (Cell Genesys)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- L-BLP25 (Biomira/Merck KGaA)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of Voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Provenge (Dendreon)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotarix (GlaxoSmithKline/Avant Immunotherapeutics)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotateq (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Streptorix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Zostavax (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - VACCINES
COMPETITOR RATIO ANALYSIS - COMPANIES
